Silence Therapeutics PLC Holding(s) in Company (7093V)
January 16 2013 - 9:16AM
UK Regulatory
TIDMSLN
RNS Number : 7093V
Silence Therapeutics PLC
16 January 2013
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)
--------------------------------------------------------------------------------------
1. Identity of the issuer or the underlying Silence Therapeutics PLC
issuer
of existing shares to which voting rights
are
attached: (ii)
-------------------------------------------------- ----------------------------------
2 Reason for the notification (please tick the appropriate box or boxes):
--------------------------------------------------------------------------------------
An acquisition or disposal of voting rights x
----------------------------------------------------------------------------- -------
An acquisition or disposal of qualifying financial instruments
which may result in the acquisition of shares already issued to
which voting rights are attached
----------------------------------------------------------------------------- -------
An acquisition or disposal of instruments with similar economic
effect to qualifying financial instruments
----------------------------------------------------------------------------- -------
An event changing the breakdown of voting rights
----------------------------------------------------------------------------- -------
Other (please
specify):
------------------- -------------------------------------------------------- -------
3. Full name of person(s) subject Richard Griffiths
to the
notification obligation: (iii)
-------------------------------------------- ----------------------------------------
4. Full name of shareholder(s)
(if different from 3.):(iv)
-------------------------------------------- ----------------------------------------
5. Date of the transaction and date 14 January 2013
on
which the threshold is crossed
or
reached: (v)
-------------------------------------------- ----------------------------------------
6. Date on which issuer notified: 16 January 2013
-------------------------------------------- ----------------------------------------
7. Threshold(s) that is/are crossed
or
reached: (vi, vii) 7%
-------------------------------------------- ----------------------------------------
8. Notified details:
----------------------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares (viii, ix)
----------------------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the triggering
of to the triggering transaction
shares transaction
if possible
using
the ISIN
CODE
------------- ------------------------------------ -----------------------------------------------------------------------
Number Number Number Number of voting % of voting rights
of of of shares rights (x)
Shares Voting
Rights
------------- ---------------- ------------------ -------------- ------------------------- ----------------------------
Direct Direct Indirect Direct Indirect
(xi) (xii)
------------- ----- ------- ------ ----- --- -------------- -------------- --------- -------------- ------------
GB0008433350
Ordinary 125,746,105 6.71% 136,961,512 136,961,512 7.31%
---------------- ------------------ -------------- -------------- --------- -------------- ------------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of voting
instrument date (xiii) Conversion Period rights that may rights
(xiv) be
acquired if the
instrument is
exercised/ converted.
---------------------- --------------- -------------------------------- ----------------------------- ------------------
C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments (xv, xvi)
----------------------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting rights
financial price date (xvii) Conversion rights instrument (xix, xx)
instrument period refers to
(xviii)
--------------- -------------- ------------- ------------------- ------------------------------ -----------------------
Nominal Delta
--------------- -------------- ------------- ------------------- ------------------------------ ------------ ---------
Total (A+B+C)
----------------------------------------------------------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
----------------------------------------------------------------- ---------------------------------------------------------
136,961,512 7.31%
----------------------------------------------------------------- ---------------------------------------------------------
9. Chain of controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held, if applicable: (xxi)
--------------------------------------------------------------------------------
Proxy Voting:
--------------------------------------------------------------------------------
10. Name of the proxy holder:
--------------------------------------------------- ---------------------------
11. Number of voting rights proxy holder will
cease
to hold:
--------------------------------------------------- ---------------------------
12. Date on which proxy holder will cease to
hold
voting rights:
--------------------------------------------------- ---------------------------
13. Additional information:
---------------------------------------- --------------------------------------
14. Contact name: Chris Hill
---------------------------------------- --------------------------------------
15. Contact telephone number: 01481 738724
---------------------------------------- --------------------------------------
Note: Annex should only be submitted to the FSA not the issuer
Annex: Notification of major interests in share
A: Identity of the persons or legal entity subject to the notification
obligation
-----------------------------------------------------------------------
Full name
(including legal form of legal entities)
-----------------------------------------------------------------------
Contact address
(registered office for legal entities)
-----------------------------------------------------------------------
Phone number & email
-----------------------------------------------------------------------
Other useful information
(at least legal representative for
legal persons)
-----------------------------------------------------------------------
B: Identity of the notifier, if applicable
-----------------------------------------------------------------------
Full name
-----------------------------------------------------------------------
Contact address
-----------------------------------------------------------------------
Phone number & email
-----------------------------------------------------------------------
Other useful information
(e.g. functional relationship with
the person or legal entity subject
to the notification obligation)
-----------------------------------------------------------------------
C: Additional information
-----------------------------------------------------------------------
For notes on how to complete form TR-1 please see the FSA website.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUNASROSAAAAR
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Nov 2023 to Nov 2024
